Disability

New York City greenlights congestion pricing – here’s how this toll plan is expected to improve traffic, air quality and public transit

Retrieved on: 
Wednesday, April 10, 2024

New York City is poised to launch the first congestion pricing plan to reduce traffic in a major U.S. metropolitan area.

Key Points: 
  • New York City is poised to launch the first congestion pricing plan to reduce traffic in a major U.S. metropolitan area.
  • Like many journeys in the Big Apple, this one has been punctuated by delays.
  • Once the system starts up, however, it’s expected to significantly reduce gridlock in Manhattan and generate billions of dollars to improve public transit citywide.
  • As an urban policy scholar, I’m looking forward to seeing New York’s plan go into effect.
  • But given the heavy costs that traffic imposes on public health and productivity, I’m encouraged to see a major U.S. city finally test this approach.

Nudging drivers

  • Congestion pricing is a response to externalities – costs or benefits that are generated by one party but incurred by another.
  • Clogged city streets and air pollution are externalities created by urban car users, many of whom live outside the city.
  • This approach is behind behavioral economics, the policy strategy of using “nudges” that preserve choice but encourage certain actions.

Public transit receives priority

  • The New York plan was presented to the board of the Metropolitan Transit Authority in November 2023 after years of study and a detailed environmental impact assessment, required by federal law.
  • It also would generate US$15 billion for capital improvements to the city’s public transit system, including making stations accessible for passengers with disabilities and buying new electric buses and commuter rail and subway cars.
  • More than 75% of all trips into the central business district are made by public transit.
  • Over several months of public hearings, the MTA heard both broad support for congestion pricing and thousands of requests for credits, discounts and exemptions, most of which were denied.
  • The limited number of exemptions includes private commuter buses, school buses and city-owned vehicles, including emergency vehicles.
  • New Jersey is suing the MTA, arguing among other things that the plan is unconstitutional because it burdens interstate commerce.

Starting the journey

  • And how will commuters respond when they find that trains and subways initially are more crowded, before capital upgrades improve the system?
  • But freedom for car users has imposed health and economic costs on millions of New Yorkers for many years.
  • But if New York’s experiment succeeds, it could provide a model and valuable insights for other traffic-clogged U.S. cities.


John Rennie Short does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

Retrieved on: 
Wednesday, April 10, 2024

The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.

Key Points: 
  • The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.
  • Based on outcome of the SARA-INT phase 2 study and on results from the SPRINTT and LIFE studies, Biophytis designed an interventional, randomized, double-blind, placebo-controlled clinical phase 3 study (the SARA-31 study), expected to include 932 subjects.
  • The poster presented at the ICFSR conference, which details the objectives and the design of the study, can be viewed by clicking on this link .
  • Stanislas Veillet, CEO of Biophytis, stated: "The SARA-31 phase 3 study will assess the efficacy and safety of RuvembriTM in the treatment of sarcopenic patients at risk of functional decline and disability.

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Retrieved on: 
Tuesday, April 9, 2024

Driven by strong patient and physician interest globally, NewAmsterdam will extend enrollment to the end of April where we expect to randomize over 9,000 patients.

Key Points: 
  • Driven by strong patient and physician interest globally, NewAmsterdam will extend enrollment to the end of April where we expect to randomize over 9,000 patients.
  • “PREVAIL, our pivotal CVOT, will potentially demonstrate that obicetrapib’s lowering of LDL-C will reduce major adverse cardiac events (“MACE”).
  • The primary objective of the study is to evaluate the effect of obicetrapib compared to placebo on MACE, including cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization.
  • “Despite widespread availability of statin therapies, CVD-related deaths are on the rise, and many patients are not at their risk-based LDL-C goals.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Monday, April 8, 2024

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

America’s VetDogs 5K Run & Dog Walk Joins Suffolk County Veterans Run Series

Retrieved on: 
Thursday, April 4, 2024

The Suffolk County Veterans Runs Series (SCVRS) will offer a variety of events in 2024, each in honor of our nation’s and region’s veterans.

Key Points: 
  • The Suffolk County Veterans Runs Series (SCVRS) will offer a variety of events in 2024, each in honor of our nation’s and region’s veterans.
  • “We thank the Scherer family and all the event organizers for welcoming America’s VetDogs into the Suffolk County Veterans Run Series,” said John Miller, president and CEO, America’s VetDogs and the Guide Dog Foundation.
  • “As we honor Chris Scherer’s enduring legacy and all our courageous veterans and service members, we eagerly anticipate witnessing the collective spirit of camaraderie as participants, both human and canine, take to the streets of Smithtown on September 28.”
    “On behalf of the Scherer family and the steering committee of the Suffolk County Veterans Run Series, we are thrilled to welcome the America’s VetDogs 5K Run and Dog Walk to the 2024 series,” said Tim Scherer, Suffolk County Veterans Run Series.
  • Congratulations to the America’s VetDogs organization and we look forward to a great 2024 run series!”
    Marcelle Leis, CMSgt (Ret), USAF/NYANG, director, Suffolk County Veterans Services Agency, Office of the County Executive, said: “We are excited to have America’s VetDogs join the Suffolk County Veteran Run Series this year.

Civil Rights Advocate Areva Martin Calls for Urgent Reform and Compassionate Response Following the Fatal Shooting of Teen in Southern California

Retrieved on: 
Thursday, April 4, 2024

The recurring theme of inadequate de-escalation tactics and the resort to lethal force, especially in situations involving individuals with mental health challenges, calls for immediate and unequivocal reform.

Key Points: 
  • The recurring theme of inadequate de-escalation tactics and the resort to lethal force, especially in situations involving individuals with mental health challenges, calls for immediate and unequivocal reform.
  • “Transparency, accountability, and a commitment to preserving life must be the guiding principles of our law enforcement.
  • The partial disclosures and the delayed relaying of critical information do not serve the cause of justice or the community's trust.
  • “Our hearts go out to the bereaved family, and we extend our full support during this incredibly challenging time.

DAV Recognizes PRIDE Industries as a Patriot Employer

Retrieved on: 
Thursday, April 4, 2024

Roseville, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PRIDE Industries, the nation’s leading employer of people with disabilities, has been named a DAV Patriot Employer.

Key Points: 
  • Roseville, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PRIDE Industries, the nation’s leading employer of people with disabilities, has been named a DAV Patriot Employer.
  • “We are honored by this important acknowledgment,” said Tim Young, Vice President, Talent Management at PRIDE Industries.
  • In addition, PRIDE Industries helps veterans access mentoring and training programs, as well as paid internships.
  • “It is with great pleasure that we recognize PRIDE Industries as a DAV Patriot Employer,” said Ryan Burgos, National Employment Director at DAV.

BridgingApps® to Curate Apps for Sentara Health Plans Members with Special Health Care Needs

Retrieved on: 
Wednesday, April 3, 2024

HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to provide expertly vetted lists of mobile device applications, or apps, to support its members who have special health care needs or disabilities.

Key Points: 
  • HOUSTON, April 03, 2024 (GLOBE NEWSWIRE) -- BridgingApps®, a program of Easter Seals Greater Houston, a 501(c)(3) non-profit organization, is partnering with Sentara Health Plans to provide expertly vetted lists of mobile device applications, or apps, to support its members who have special health care needs or disabilities.
  • Later this year, qualified Sentara Health Plans members will have access to a comprehensive list of curated apps recommended by BridgingApps Care Managers.
  • This will better equip members to manage their health decisions and develop important skill sets, ultimately improving their health and quality of life.
  • BridgingApps’ free App Search Tool, Search.BridgingApps.org , houses a database of apps trialed and reviewed by therapists, special education teachers, experts, and special needs users.

Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate

Retrieved on: 
Monday, April 1, 2024

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today issued an open letter from Larry Jasinski, Chief Executive Officer, to shareholders discussing the Company’s progress with the Centers for Medicare & Medicaid Services (“CMS”) to establish a payment rate for ReWalk Personal Exoskeletons. The full letter is published below:

Key Points: 
  • As a result of the deferral, the payment rate is not included in CMS’ April 2024 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) fee schedule of Medicare payment rates that are effective April 1.
  • Our active engagement with CMS is ongoing and we work to establish the payment rate as soon as possible.
  • Until a payment rate for exoskeletons is added to the DMEPOS schedule, the Medicare Administrative Contractors (“MACs”) still have authority to approve and pay claims on a case-by-case basis with discretion to set the payment rate.
  • Lifeward intends to submit an additional 60-75 additional Medicare claims by the end of 2024 to accelerate its momentum in expanding access for qualified Medicare beneficiaries.

Civil Rights Leader Areva Martin Intensifies Call for Justice in the Controversial Shooting of Autistic Teen, Challenges “Attempted Murder of a Peace Officer” Narrative

Retrieved on: 
Friday, March 29, 2024

The Sheriff’s Department's characterization of the incident as “Attempted Murder of a Peace Officer” in its media advisory demands examination.

Key Points: 
  • The Sheriff’s Department's characterization of the incident as “Attempted Murder of a Peace Officer” in its media advisory demands examination.
  • Instead, the department reflexively names their own deputy as a victim of Ryan's alleged criminal behavior.
  • "We reiterate our call for the full and immediate release of all body-camera footage and other evidence pertinent to the incident.
  • We recognize the intersectionality of individuals with disabilities and that their fight for disability rights is inextricably tied to the fight for racial justice and the civil rights of all people.